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Introduction: UK CF Trust advocates an annual OGTT in adult CF patients. Yung
et al 1999 devised a selective approach to determine who should have an OGTT
based on any one of the following: random blood glucose (RBG) 11.1mmol/l,
HbA1C > 6.1%, clinical symptoms, unexplained weight loss >5% and FEV1 decline
>10% per annum. We compared the clinical accuracy in screening for CFRD using
(i) a selective approach based on a combination of clinical and biochemical criteria;
(ii) an unselected annual OGTT.
Methods: 100 consecutive adult CF patients (without CFRD) were recruited to
a prospective study (March-December 2009). All underwent an OGTT and the
selective screening protocol by 2 experienced CF doctors who were blinded to the
OGTT result.
Results: 94 patients’ (mean age = 31±9(SD), 38% female, 79% pancreatic in-
sufﬁcient) data were analysed (6 patients were excluded − insufﬁcient data).
RBG> 11.0mmol/l, n = 6 (mean glucose (all patients) = 6.0±2.5); HbA1C > 6.1%,
n = 30 (mean (all patients) = 5.9±0.7); ↓ FEV1, n = 8; ↓Weight, n = 6. OGTT at
0 min, glucose >7mmol/l, n = 0; at 120 min >11.0 (WHO diabetic range), n = 6; at
120 min 7.8–11.0 (WHO impaired glucose tolerance (IGT) range), n = 8. 42 patients
were selected for OGTT by screening (inter-reviewer agreement 100%). 1 patient
in the diabetic range (subsequent glucose monitoring was normal) and 2 in the IGT
range were not selected for OGTT. Sensitivity = 83.3% and speciﬁcity = 58.0%
(positive predictive value = 11.9% and negative predictive value = 98.1%).
Conclusion: A selective approach for diagnosing CFRD provides an acceptable
negative predictive value and avoids the need for an OGTT (a time and resource
consuming test) in the majority of patients.
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Background: The current UK gold standard for assessing glycaemia in CF is oral
glucose tolerance testing (OGTT), with serial capillary blood glucose (CBG) if
abnormal. Elevated glycosylated haemoglobin (HbA1c) levels are to be included in
diagnostic criteria for CFRD in forthcoming US consensus guidelines. Continual
glucose monitoring studies (CGMS) are a novel means of assessing glycaemia. A
subcutaneous sensor reads interstitial glucose, producing a 72 hour trace. Regular
CBGs are needed during CGMS for calibration. The pictorial CGMS result may
be more useful than conventional tests in reﬂecting ‘real life’ glycaemia, and also
provides a clear foundation for further management.
Aim: To look for a link between mean CGMS glucose level and HbA1c in stable
adults with CF.
Methods: 39 clinically stable adults with CF had concurrent CGMS, OGTT and
HbA1c testing.
Results: All completed the protocol: mean (SD) age 30.4 (11.8) years, 23 (59%)
male. Mean CGMS glucose level correlated with HbA1c level, r = 0.825, P< 0.001
(Pearson’s correlation coefﬁcient).




n = 16 (41.0%)
Impaired,
n = 8 (20.5%)
Diabetic,
n = 15 (38.5%)
HbA1c (%), mean (SD) 6.2 (1.0) 5.6 (0.3) 5.9 (0.6) 7.1 (1.0)
Mean CGMS glucose
(mmol/L), mean (SD)
6.8 (1.6) 6.0 (0.8) 6.4 (2.0) 7.8 (1.5)
Discussion: In our study mean 3 day glucose by CGMS correlated strongly
with HbA1c, suggesting that mean CGMS glucose could be a useful measure of
glycaemia in CF. A CGMS trace may offer more helpful information to patients
and professionals than CBG, OGTT and HbA1c results. Work is ongoing to fully
and robustly validate CGMS in our adult patients and also explore how acceptable
this method is to patients.
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Objectives and Methods: 24 h UCP rate is a noninvasive measure of insulin
production which is highly correlated with insulin, fasting and peak of C-peptide
after glucagon stimulation. 24 h UCP excretion is prospectively followed for two
years in 33 CF patients (age = 13.2±6 years). Our patients have no overt renal
disease. We use an ICMA assay for 24 h urine samples (Cobas kit on Modular E).
We express UCP rates in mcg/creatinine g and in mcg/m2. 49 urinary tests
are realized compared with clinical status (Shwachman score, BMI, FEV1) and
glycemic status (fasting glycemia, glycemia 2 h after charge and HbA1c) in order
to study the trend of insulin secretion in CF patients.
Results: In our CF patients mean UCP values are higher. We ﬁnd also slightly
lower levels in males than in females. We observe a slight decrease of UCP rate
with age. But we discover no correlation with Shwachman score, BMI, FEV1,
fasting glycemia, glycemia 2 h after charge and HbA1c. Six CF patients (12.2%)
exhibit a diabetes, thirteen (26.5%) an impaired glucose tolerance (IGT) but UCP
rates are similar in all patient groups. Along, we observe obvious variations of the
glycemic status. In 4 IGT patients UCP levels are clearly higher.
Conclusions: Usually, C-peptide secretion is positively correlated with age, BMI
and body surface. UCP can also be affected by diet and physical exercise. Therefore,
our data suggest a slight decrease of C-peptide excretion and insulin production.
The pattern of IGT patients with higher levels of UCP may be explained either by
a lower insulin sensitivity or by a moderate hyperglycemia which affects C-peptide
renal handling. We cannot exclude difﬁculties in 24 h collection.
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An oral glucose tolerance test (oGTT) has become part of standard care in cystic
ﬁbrosis (CF). In addition to detect manifest diabetes mellitus (CFRD), the test
also identiﬁes individuals with a hyperglycaemic response indicating an increased
risk for developing diabetes. However, up to 15% of patients with CF develop
hypoglycaemia during an oGTT. The objective of this study was to determine the
prognostic value of such a hypoglycaemic response to predict future CFRD. Data
from 827 patients who participated in an international prospective study on the
incidence of CFRD were analyzed. All patients had at least two valid oGTTs each
and a hypoglycaemic or normal response to the ﬁrst challenge. Mean time between
ﬁrst and last available oGTT was 3.5±1.8 years. There was no difference between
the patients with an entirely normal (n = 779) or a hypoglycaemic response (n = 48)
to the ﬁrst oGTT in the incidence of a diabetic (9.9 vs. 10.4%) or a hyperglycaemic
(20.5 vs. 22.9%) response at the last oGTT. In conclusion, a hypoglycaemic response
to an oGTT is less common than previously reported and does not indicate a risk
for future CFRD or impaired glucose tolerance, at least not for the next 3.5 years.
